RBT

RBT JSC is an innovative biotechnology company, developer of the Betusphere platform for the creation and production of subunit vaccines with a high safety profile. The company was established in 2011 for research and development of innovative medicines. It develops complex projects in the field of biopharmaceuticals.
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

RBT balance sheet

Report period2022 2023
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

RBT cash flows

Report period2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
EPS

RBT multipliers

Report period2022 2023
P/E
E/P
P/B
P/S
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

RBT profitability

Report period2022 2023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
RBT assets
RBT cash flows

RBT dividend policy

The Company does not pay dividends

RBT shares

TickerNameTypeNominal valueISINPrice
RBTY:RMRBTCommon shareRUB 0.01RU000A105Y55RUB 174.8
RBT news
11.10.2024
Artgen Biotech Group is investing in the development of a platform for creating new subunit vaccines based on surface recombinant proteins and spherical adjuvant particles. Developer of the technology platform is RBT, a company within the Artgen Biotech group. Total investment in the development of the production component of the platform by RBT, including f...
Source: {source} pictogram artgen.ru
Pictogram next
All RBT news
General information
Company nameRBT
Tags#moex otc, #biotechnology, #pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressMoskva, pr-kt Vernadskogo 96
Mailing addressMoskva, pr-kt Vernadskogo 96
Websiterbiotech.ru
Information disclosuree-disclosure.ru